Adjuvant Treatment in Colorectal Cancer

Ivanov, Krasimir; Kolev, Nikola; Shterev, Ivan; Tonev, Anton; ValentinIgnatov,; Bojkov, Vasil; Kirilova, T.

doi:10.5772/56914

Cited by 5 publications

(7 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prognostic factors are particularly useful in the context of stage II colon cancer, where benefits of cytotoxic adjuvant therapy are more controversial than in stage III disease (13). In our study for all patients the mean number of histologically examined lymph nodes was less than 10 due to the large number of Nx group patients.…”

Section: Discussionmentioning

confidence: 91%

2-year single center clinical experience in patients with colon cancer stage II and III receiving adjuvant chemotherapy

Conev

Donev

Dimitrová

et al. 2015

SSM

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 91%

2-year single center clinical experience in patients with colon cancer stage II and III receiving adjuvant chemotherapy

Conev

Donev

Dimitrová

et al. 2015

SSM

View full text Add to dashboard Cite

“…g. Panitumumab, a monoclonal antibody to EGFR (fully humanized), that blocks the ligandbinding site [188].…”

Section: Modulation Of Apoptosis By Combined Therapymentioning

confidence: 99%

Modulation of Apoptosis in Colon Cancer Cells by Bioactive Compounds

Bostan¹,

Mihăilă²,

Hotnog³

et al. 2016

Colorectal Cancer - From Pathogenesis to Treatment

View full text Add to dashboard Cite

A big challenge for a successful colon cancer treatment is the lack of eradication of the entire tumour cell population and consequent development of chemoresistance. Control of cell number from tissues and elimination of cells predisposed to malignant transformation, having an aberrant cell cycle or presenting DNA mutations, might be performed by a cellular 'suicide' mechanism-the programmed cell death, or apoptosis. Coordinated activation and execution of multiple subprograms are needed, added by a good knowledge of the basic components of the death machinery, besides their interaction to regulate apoptosis in a coordinated manner. Triggering apoptosis in target cells is a key mechanism by which chemotherapy promotes cell killing. Many anti-cancer drugs act during physiological pathways of apoptosis, leading to tumour cell destruction. New therapeutic approaches in cancer induce tumour cells to undergo apoptosis and break the cancer cell resistance to apoptosis commands. Administrations of natural compounds that prevent induction, inhibit or delay the progression of cancer, or induce inhibition or reversal of carcinogenesis at a premalignant stage represent chemoprevention strategies. Several natural compounds have been shown to be promising based on their anti-cancer effects and low toxicity; alternative approaches might be taken into account to obtain a stronger anti-tumour response when lower concentrations of anti-cancer drugs are used, and to diminish the undesirable side-effects.

show abstract

“…To deal with CRC progression and metastasis, different staging and classification systems together with different modes of treatment have been established throughout the years [4,5]. Despite the advancements made in therapeutic strategies, CRC mortality rate remains high, and development of chemoresistance due to different circumstances remains a major constraint to patients being treated [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Utilising Proteomics and Organoid Cultures for Predicting Treatment Response in Colorectal Cancer

Micallef¹,

Baron²

2022

Recent Understanding of Colorectal Cancer Treatment

View full text Add to dashboard Cite

Colorectal cancer (CRC) remains one of the most frequently diagnosed tumours worldwide. Despite advances in surgical intervention and therapeutics, development of chemoresistance remains a challenge to treating CRC. Predicting treatment response in CRC has strongly relied on genomics, transcriptomics and epigenomics, combined with different cancer staging and classification systems. Despite being beneficial, these omics technologies fail to provide any assessment at a protein level. Thus, having high-throughput tools that assess tumour response to therapy at a protein level will definitely complement the current approaches. In this regard, the field of proteomics holds promise to understand treatment response in tumours. Additionally, patient-derived tumour organoids are replacing the traditional cell lines and xenograft models as the preferred in vitro models for predicting clinical response due to being a better representative model of typical tumour characteristics in vivo. Combining proteomics and tumour organoids can provide more personalised and optimal treatments for CRC in the coming years. This chapter aims to provide an overview of the progress made in proteomic research and use of organoids for understanding CRC treatment response, together with discussing the strengths and limitations of these two approaches when linked together. This overview will then be used to propose future perspectives.

show abstract

Adjuvant Treatment in Colorectal Cancer

Cited by 5 publications

References 69 publications

2-year single center clinical experience in patients with colon cancer stage II and III receiving adjuvant chemotherapy

2-year single center clinical experience in patients with colon cancer stage II and III receiving adjuvant chemotherapy

Modulation of Apoptosis in Colon Cancer Cells by Bioactive Compounds

Utilising Proteomics and Organoid Cultures for Predicting Treatment Response in Colorectal Cancer

Contact Info

Product

Resources

About